Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249096 | 1.00 | PARP1 (0.42) | PARP1HRH3CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL4249098 | 1.00 | PARP1 (0.42) | PARP1HRH3CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL3918173 | 0.88 | CYP2D6 (0.42) | PARP1HRH3CYP2D6SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL6658313 | 0.79 | PARP1 (0.38) | PARP1HRH3CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL4241067 | 0.78 | HRH3 (0.52) | PARP1HRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3915676 | 0.78 | HRH3 (0.52) | PARP1HRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4241064 | 0.78 | HRH3 (0.52) | PARP1HRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3909127 | 0.77 | HRH3 (0.64) | PARP1HRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2250029 | 0.76 | PARP1 (0.39) | PARP1 | |
| SCHEMBL2250025 | 0.76 | PARP1 (0.39) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029551-B1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MSD ITALIA SRL (IT) | 2018-10-31 | — | — | EP | disclosed |
| US-8188084-B2 | Pyridinone and pyridazinone derivatives as inhibitors of poly (ADP-ribose) polymerase (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. (IT) | 2012-05-29 | — | — | US | disclosed |
| US-20090176765-A1 | Pyridinone and Pyridazinone Derivatives as Inhibitors of Poly (Adp-Ribose) Polymerase (Parp) | MSD ITALIA S.R.L. (IT) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176765-A1 | Pyridinone and Pyridazinone Derivatives as Inhibitors of Poly (Adp-Ribose) Polymerase (Parp) | PARP1, PARP2, PARP3 | PARP1 1/4885HRH3 1527/4885CYP2D6 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.